0

The Cost-Effectiveness of Blue Light Cystoscopy in Bladder Cancer Detection: United States Projections Based on Clinical Data Showing 4.5 Years of Follow Up After a Single Hexaminolevulinate Hydrochloride Instillation

Susan S Garfield, Meghan B Gavaghan, Shannon O Armstrong, J Stephen Jones

Can J Urol. 2013 Apr;20(2):6682-9.

PMID: 23587507

Abstract:

Introduction:
Several studies, including the recently published phase III study by Stenzl and colleagues have demonstrated that hexaminolevulinate hydrochloride, when used with blue light fluorescence cystoscopy, improves detection of non-muscle invasive bladder tumors compared to white light cystoscopy and transurethral resection of bladder tumors (TURB) alone.
Materials and methods:
The objective of this study was to conduct a detailed assessment of the cost-effectiveness of using hexaminolevulinate hydrochloride with blue light cystoscopy as an adjunct to white light versus white light cystoscopy alone at time of initial TURB in the United States. A probabilistic decision tree model, using TreeAge Pro 2011 software, was developed using base case scenario cost and utility estimates.
Results:
Incorporation of hexaminolevulinate hydrochloride into diagnostic cystoscopy results in lower costs over 5 years ($25,921) as compared to those patients who initially receive white light cystoscopy ($30,581). Those patients who initially receive hexaminolevulinate hydrochloride blue light TURB also experience a lower overall cancer burden.
Conclusions:
Hexaminolevulinate hydrochloride may be cost effective when used at first TURB for patients with suspected new or recurrent non-muscle invasive bladder cancer.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP140898915 Hexaminolevulinate hydrochloride Hexaminolevulinate hydrochloride 140898-91-5 Price
qrcode